GPC Biotech AG emerged successfully from its legal dispute with partner Spectrum Pharmaceuticals Inc., although the circumstances surrounding the case altered radically in the interim. (BioWorld International)

LONDON - Ark Therapeutics Group plc has backed off from moving Vitor, its treatment for cancer cachexia, into a full-scale Phase III trial after talks with the FDA. The company instead is opting to carry out a 60-patient pilot to gather further intelligence on endpoints and consider the design of the definitive 250 patient Phase III study. (BioWorld International)